Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Pjmcgra
The granted ILI patient will have a value, however this will pale into insignificance when compared to the value once SNG001 obtains authorisation.
Remember although the ILI granted patent has only approximately 6years left to run, once authorised there are two ways to extend this by means of application. These being via a SPC (Supplementary Protection Certificate) or Exclusivity.
1) SPC (Supplementary Protection Certificate) up to 5yrs + an extra 6 months for Paediatric use.
This requires SNG001 to be authorised before an application can be made.
2) The preferable one, ‘Exclusivity’, this again requires SNG001 to be authorised prior to an application being made.
Exclusivity can give additional protection for instance in the U.S. up to 12yrs, EU about to change from approximately 8years to 11years 6months.
Plus ‘’Exclusivity’’ affords greater protection (governmental) regarding possible future infringement.
In both cases the extensions are to compensate the patent owner/developer for the time taken in obtaining authorisation, (trials etc.)
However, the additional years if applied can never extend the original patent beyond its original lifespan which is 20years.
As an example, for ‘Exclusivity’ in the U.S. (up to 12yrs) if a drug is authorised with say 12yrs left on its patent life, exclusivity would only extend it back to 20years and NOT 12yrs plus 12yrs = 24yrs.
All in all, the SNG001 ILI granted patent has a healthy future once authorised plus with the potential patent extensions
will make SNG001 very attractive to BP if they’re not already.
Lastly, SNG have 2 patent applications in the pipeline for SNG001 these being: Covid and COPD/corticosteroid use.
They’ve been running the application/examination process for coming up to 4years now.
If all goes well with the applications and the eventual authorisation of SNG001 the future is bright imo.
Professional
Do you really have a grasp of IP value, you certainly didn’t give that impression when agreeing with Sukura7 regarding SNG’s IP.
As usual, you were playing mind games then and continue to do so with the unwary.
“And let me be clear ( as this is obviously to difficult for you to work out yourself). I do this with a very good grasp of ip value and if i invest this amount you and all others will be fully diluted so lets hope for you that if money is needed it will be via JV or equity raise for everybody. Cheers”
RE: A Plan? A product? SNG00128 Jan 2024 16:22
Sakura it is clear your knowledge is superieur to the wannabees...
Doc.D
Whilst we have no official knowledge of the nature of the relationship with the Casanovalabs regarding Universal or SGN’s P2, (apart from the AGM), I would suggest an in-kind collaboration would benefit all parties involved at this stage of their commercial development including Casanovalabs.
Spacman
“Equally, much as Synairgen may be dependent on Casanovalabs, the latter doesn't make any money unless Synairgen succeeds. So all very "symbiotic"...
Apart from the obvious advantages for SNG001, the Casanova assay test has scope for usefulness in a number applications, especially vaccine susceptibility.
“The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and
COVID-19 vaccines, to assess risk for vaccine- associated disease and adverse events, and for evaluation, treatment and management of patients who develop vaccine-associated disease”
Doc.Daneeka,
None of the information from my past posts or present came from a post AGM pub chat.
The information in my notes are a reflection of the AGM or from members of the BoD post AGM chat.
The impression I took from the line “US gov conversations are positive. U.K. government more frustrating.” was in reference to the NIH and MHRA.
Although it’s apparent these trials are breaking new ground on many fronts, personally I remain confident Synairgen will meet their timeframe of H1 for starting the trials.
Spacman
Interested to know why you think it is preferable to push for a sale of the company for circa 200million as opposed to waiting for the outcome of a funding transaction running in parallel, as you suggest.
Ignoring for the moment, secured before the auditors sign off tag?
Professional
My opinion, I think your assumptions are wrong on both counts.
“To be clear : them offering to buy the conpany for the cheap ( say 20p) would still be a good possibility and i think majority will accept. 100% certain i would. Cheers”
Further to my last post I will add, the original filing dates become Priority Dates in respect of IP rights going forward.
Having extensively studied the previous Synairgen patent applications I have noted nothing regarding ‘Viral Persistence’
So don’t be surprised if an application pops up in the future. Will keep you posted if it does.
Manifesto,
Synairgen to date have never made their intentions known publicly when fIling a new patent application.
For the obvious reasons, a new filing application is not in the public domain (published) for approximately 18months.
This enables the applicant to finely hone the application within reason, along with filling additional supportive applications. Similar to the published Covid application which encompassed 3 eventual published applications that were formed into one application going forward for examination and consideration for Grant.
In the world of maintaining IP confidentiality from competitors this is a normal and wise course of action.
TommyD_19 does make a valid point regarding “viral persistence “ and the possibilities for SNG001.
Spacman,
Our views on the immediate way forward differ, My preference is to give the BoD this last opportunity to achieve their stated H1 plans and goals, starting the Phase2 trials. These limited trials once started should not take an inordinate time to complete.
If they are successful, it will facilitate the ability for the BoD to maximise the opportunities to negotiate from a relative position of strength, be it, J/V or other options that may arise from interested BP’s/parties.
Should they fail to start the trials in H1 and another delay ensues, they will have to answer for their failure at the next AGM or even beforehand and bear the consequences. Until such time I’m of mind to give them this last chance for their current H1 plans.